Otsuka taps Shape in deal to design eye gene therapies
BioPharma
Source: biopharmadive.com
Page 2 - Shape Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Shape Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Shape Therapeutics Today - Breaking & Trending Today
Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies
To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.
Source: biospace.com
Shape, Otsuka ink $1.5B gene therapy alliance targeting ocular diseases
In its second big pharma deal to date, Shape Therapeutics Inc. drew Otsuka Pharmaceutical Co. Ltd. to the table in a potential $1.5 billion-plus collaboration initially aimed at developing gene therapies for ocular diseases. The multitarget agreement, which includes options for additional targets and tissue types, will combine Shape’s AI-driven adeno-associated virus (AAV) platform and Otsuka’s expertise in ophthalmology to develop intravitreally delivered AAV therapies.
Source: bioworld.com
After the Moderna COVID-19 vaccine, Flagship a new hit
The Moderna COVID-19 vaccine was the ultimate home run for this biotech venture firm. It’s a tough act to follow.
Source: fortune.com
Seven Biopharma Trends to Watch in 2023
Key trends include fewer and slower financings, a surge of decisive data readouts for cancer vaccines, and further development of mRNA, cell, and gene therapies.
Source: genengnews.com